Dr. Amit Rhakit is the Chief Medical Officer at BlueRock Therapeutics, where he focuses on cutting-edge cell therapies for Parkinson's disease. He delves into how their therapy, bemdaneprocel, restores dopamine-producing neurons, contrasting it with conventional treatments. The discussion highlights the significant benefits these advancements could have on patient quality of life. Rhakit also shares insights on the personal stories of those living with Parkinson's, emphasizing the transformative potential of innovative therapies in managing symptoms.